Captura Biopharma, LLC is an emerging biotechnology company engaged in the development and commercialization of heavy metal chelators useful in the treatment of internal radionuclide contamination and heavy metal poisoning. Its lead chelation candidate, C2E2, will be the world's first oral treatment indicated for internal radiation contamination and has been proven in efficacy studies to target select heavy metals, notably americium, plutonium, and lead. Heavy metal contamination, including exposure to transuranic elements, is on the rise. UNICEF estimates one third of the world's children suffer from lead poisoning and its associated detrimental neurological effects. Post-COVID lead-poisoning incidence is expected to increase due to pandemic-related supply chain issues with the current standard of care drug, succimer. Captura also intends to pursue indications for cadmium poisoning as well as rare-earth-metal poisoning. Increased investment in electric vehicles, solar power, and lithium-ion batteries will drive cadmium use and associated toxic exposure evident in manufacturing and disposal. Captura is uniquely positioned to serve these multi-billion-dollar markets with an easily accessible and useable product formulated to meet situation requirements.